Introduction In Lymphoid Hypereosinophilic Syndrome (LHES) an aberrant clonal T cell population drives a persistent eosinophilia via Th2 cytokine production. Clinical manifestations classically include an intensely pruritic rash. Janus Kinases Inhibitors (JAKi) such as tofacitinib have recently emerged as a therapeutic for inflammatory diseases and has unique anti-itch properties. We present a case of LHES with cutaneous involvement successfully managed with tofacitinib.
